1st Quarter - Report

ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.

Firm
Client
Income
—
Expenses
$560,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1300/S. 297 PSA screening bills; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
JONATHAN OEHMEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 297 (119th), H.R. 1300 (119th)

Health Issues HCR

Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; Issues related to implementation of the Inflation Reduction Act (H.R. 5376).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
JONATHAN OEHMEN —

Contacted: Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5376 (119th), H.R. 1300 (119th), S. 297 (119th)

Copyright/Patent/Trademark CPT

Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
JONATHAN OEHMEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Insurance INS

Issues related to Pharmacy Benefit Manager reform, S. 392 Give Kids a Chance Act; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
JONATHAN OEHMEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1300 (119th), S. 297 (119th), S. 392 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.